Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis

Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis

Visceral leishmaniasis (VL) is a systemic parasitic disease that leads to high rates of morbidity and mortality in humans worldwide. There is a great need to develop new drugs and novel strategies to make chemotherapy for this disease more efficacious and well tolerated. Recent reports on the immuno...

Full description

Bibliographic Details
Main Authors:	Guilherme S. Ramos, Virgínia M.R. Vallejos, Marina S. Ladeira, Priscila G. Reis, Daniel M. Souza, Yuri A. Machado, Luiz O. Ladeira, Maurício B.V. Pinheiro, Maria N. Melo, Ricardo T. Fujiwara, Frédéric Frézard
Format:	Article
Language:	English
Published:	Elsevier 2021-02-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Fullerol Fullerenol Liposomes Leishmaniasis Immunomodulation Drug delivery
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332220313135

Similar Items

SÍNTESIS DE FULLEROLES A PARTIR DE UN DERIVADO BROMADO DE C60
by: Álvaro Duarte, et al.
Published: (2009-06-01)

Fullerol Nanocatalysis and Trimodal Surface Plasmon Resonance for the Determination of Isocarbophos
by: Huixiang Ouyang, et al.
Published: (2020-08-01)

Fullerol-hydrogel microfluidic spheres for in situ redox regulation of stem cell fate and refractory bone healing
by: Jielai Yang, et al.
Published: (2021-12-01)

Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
by: D.A. Schettini, et al.
Published: (2005-12-01)

Visceral Leishmaniasis in Children in Southern Turkey: Evaluation of Clinical and Laboratory Findings and Liposomal Amphotericin B Treatment
by: Barbaros Şahin Karagün, et al.
Published: (2019-06-01)

Liposomes containing the imiquimod adjuvant as a vaccine in the cutaneous leishmaniasis model
by: Ahmad Mehravaran, et al.
Published: (2020-01-01)

Novel methods for the encapsulation of meglumine antimoniate into liposomes
by: F. Frézard, et al.
Published: (2000-07-01)

Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant Leishmania donovani With Increased Efficacy
by: Sandip Mukherjee, et al.
Published: (2020-11-01)

Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis
by: Daniela P. Lage, et al.
Published: (2020-06-01)

Distribution of liposome-encapsulated antimony in dogs
by: D.A. Schettini, et al.
Published: (2003-02-01)

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
by: Dinesh Mondal, et al.
Published: (2019-10-01)

Assessment of the Effects of a Novel Herbal Immunomodulator Drug (IMOD) on Cytokine Profiles in Experimental Canine Visceral Leishmaniasis: a Preliminary Survey
by: Abdolali Malmasi, et al.
Published: (2014-09-01)

Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal amphotericin B
by: Georgiadou Sarah, et al.
Published: (2012-06-01)

Visceral leishmaniasis in pregnant women from Rio Grande do Norte, Brazil: A case report and literature review
by: Francielly Tertulino Cunha, et al.
Published: (2019-02-01)

Fullerol C<sub>60</sub>(OH)<sub>24</sub> Nanoparticles Affect Secondary Metabolite Profile of Important Foodborne Mycotoxigenic Fungi In Vitro
by: Tihomir Kovač, et al.
Published: (2020-03-01)

Changing Pattern of Visceral Leishmaniasis, United Kingdom, 1985-2004
by: Aeesha N.J. Malik, et al.
Published: (2006-08-01)

Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients
by: Wim Adriaensen, et al.
Published: (2018-01-01)

Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice
by: Omid Chavoshian, et al.
Published: (2013-09-01)

Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
by: Zili Gu, et al.
Published: (2020-11-01)

Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis
by: Shirzadi MR
Published: (2019-04-01)

Immunological and Toxicological Considerations for the Design of Liposomes
by: Collin T. Inglut, et al.
Published: (2020-01-01)

Treatment of post kala-azar dermal leishmaniasis with fungisome – A novel Indian liposomal amphotericin B
by: Akansha Anil Chadha, et al.
Published: (2020-01-01)

Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (SinaAmpholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis
by: Seyed Ebrahim Eskandari, et al.
Published: (2018-07-01)

Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece
by: Sarah P. Georgiadou, et al.
Published: (2015-05-01)

Pentavalent Antimonials: New Perspectives for Old Drugs
by: Raul R. Ribeiro, et al.
Published: (2009-06-01)

Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell
by: M. Junaid Dar, et al.
Published: (2018-01-01)

Influence of fullerenol C60(OH)24 on enzime status in serum of rats after single dose administration of doxorubicine
by: Govedarica Biljana Č., et al.
Published: (2008-01-01)

Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis
by: Abdus Sabur, et al.
Published: (2018-01-01)

Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate
by: Gregorio Basile, et al.
Published: (2020-08-01)

Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis
by: Maiara Maria Romanelli, et al.
Published: (2019-10-01)

Exploring the role of medicinal plant-based immunomodulators for effective therapy of leishmaniasis
by: Garima eChouhan, et al.
Published: (2014-05-01)

Evaluation of the schistosomicidal efficacy of liposome - Entrapped Oxamniquine
by: Frédéric Frézard, et al.
Published: (1997-03-01)

Antileishmanial IgG and IgE antibodies recognize predominantly carbohydrate epitopes of glycosylated antigens in visceral leishmaniasis
by: AM Atta, et al.
Published: (2004-08-01)

Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity
by: Samanta Etel Treiger Borborema, et al.
Published: (2016-04-01)

Fullerol C<sub>60</sub>(OH)<sub>24</sub> Nanoparticles and Drought Impact on Wheat (<i>Triticum aestivum</i> L.) during Growth and Infection with <i>Aspergillus flavus</i>
by: Tihomir Kovač, et al.
Published: (2021-03-01)

Cytotoxicological Response to Engineered Nanomaterials: A Pathway-Driven Process
by: Romoser, Amelia Antonia
Published: (2012)

Liposomes: from biophysics to the design of peptide vaccines
by: F. Frézard
Published: (1999-02-01)

Urban Visceral Leishmaniasis in Venezuela
by: CM Aguilar, et al.
Published: (1998-01-01)

Hypergolics in Carbon Nanomaterials Synthesis: New Paradigms and Perspectives
by: Nikolaos Chalmpes, et al.
Published: (2020-05-01)

Leishmanicidal and Immunomodulatory Activities of the Palladacycle Complex DPPE 1.1, a Potential Candidate for Treatment of Cutaneous Leishmaniasis
by: Isabela B. dos Santos, et al.
Published: (2018-07-01)